GlassScriptPhysician profile
Kim Kuhar
NPI 1508898396
$2,248.07
in general payments reported to CMS, 2019-2025
23 companies · $181 in 2025
The $181 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $321 · 2020: $17.63 · 2021: $256 · 2022: $454 · 2023: $685 · 2024: $334 · 2025: $181.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,016 · Education: $184.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,016.00 |
| Education | $184.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $352.20 | 2019-2025 | Veozah |
| Astrazeneca Pharmaceuticals LP | $265.25 | 2019-2024 | Farxiga, Breztri |
| Pfizer INC. | $210.04 | 2019-2025 | |
| Abbvie INC. | $193.28 | 2021-2024 | |
| Abbott Laboratories | $190.20 | 2021-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $165.25 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $143.27 | 2019-2024 | Wegovy |
| Exact Sciences Corporation | $131.07 | 2023-2024 | Cologuard Collection Kit |
| Lilly USA, LLC | $89.28 | 2022-2025 | Mounjaro, Zepbound |
| Corcept Therapeutics | $86.67 | 2023 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $73.99 | 2021-2024 | |
| Amgen INC. | $64.35 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.29 | 2022-2024 | Jardiance |
| Janssen Pharmaceuticals, INC | $38.06 | 2019 | |
| Allergan, INC. | $37.79 | 2019-2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $27.89 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $27.51 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $27.04 | 2022 | |
| Sunovion Pharmaceuticals INC. | $19.19 | 2021 | |
| Sanofi Pasteur INC. | $17.70 | 2019 | |
| Vertos Medical, INC. | $14.83 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $14.22 | 2019 | |
| Amarin Pharma, INC. | $13.70 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kim Kuhar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.